ENTITY
BIOS0635-048
BIOS0635-048
PulseAugur coverage of BIOS0635-048 — every cluster mentioning BIOS0635-048 across labs, papers, and developer communities, ranked by signal.
Total · 30d
2
2 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
1
1 over 90d
TIER MIX · 90D
TOPICS
TIMELINE
- 2026-07-27 product_launch BaiCheng Pharmaceutical's innovative drug BIOS0635-048 tablets received clinical trial approval from the National Medical Products Administration. source
SENTIMENT · 30D
1 day(s) with sentiment data
RECENT · PAGE 1/1 · 2 TOTAL
-
7-Eleven parent abandons Polish investment; AI leader predicts 'old world's' end
Seven & i Holdings, the parent company of 7-Eleven, has decided not to proceed with its investment in Żabka Group, Poland's largest convenience store operator, due to disagreements over investment terms. The potential d…
-
BaiCheng Pharmaceutical's novel cancer drug BIOS0635-048 receives clinical trial approval
BaiCheng Pharmaceutical has received approval from China's National Medical Products Administration for its innovative drug, BIOS0635-048 tablets. This new molecular inhibitor is designed for the treatment of various so…